What is the recommended enoxaparin (Clexane) dosage for acute coronary syndrome, including dosing adjustments based on patient weight and renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Enoxaparin (Clexane) Dosing in Acute Coronary Syndrome

For ACS, use enoxaparin 1 mg/kg subcutaneously every 12 hours as initial therapy, with mandatory dose reduction to 1 mg/kg once daily if creatinine clearance is below 30 mL/min. 1

Standard Dosing Protocol

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide the definitive dosing framework 1:

Initial Medical Management

  • Standard dose: 1 mg/kg subcutaneous every 12 hours
  • Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg subcutaneous once daily (every 24 hours)

For Patients Receiving Fibrinolytic Therapy

Age <75 years:

  • 30 mg IV bolus
  • Followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours
  • Maximum 100 mg for the first 2 doses

Age ≥75 years:

  • No bolus (critical pitfall to avoid)
  • 0.75 mg/kg subcutaneous every 12 hours
  • Maximum 75 mg for the first 2 doses

Regardless of age with CrCl <30 mL/min:

  • 1 mg/kg subcutaneous every 24 hours

To Support PCI

If patient already on enoxaparin:

  • Last dose 8-12 hours ago OR only 1 dose given: Give 0.3 mg IV
  • Last dose within 8 hours: No additional dose needed

If no prior anticoagulation:

  • 0.5-0.75 mg/kg IV bolus 1

Critical Dosing Adjustments

Renal Function

The most important adjustment is for renal impairment. Research confirms enoxaparin clearance decreases by 31% in moderate renal impairment and 44% in severe renal impairment, leading to significant accumulation with standard dosing 2. Always calculate creatinine clearance using the Cockcroft-Gault equation before initiating therapy.

Obesity Considerations

While the guidelines specify weight-based dosing without upper limits, emerging evidence suggests potential issues in extreme obesity. Research shows that in patients >150 kg, standard 1 mg/kg dosing may increase bleeding risk 3. However, the 2025 guidelines do not recommend dose capping, and you should follow guideline recommendations of 1 mg/kg dosing 1. If weight exceeds 150 kg, consider anti-Xa monitoring if available, targeting peak levels of 0.5-1.0 IU/mL drawn 4 hours after the third dose.

Common Pitfalls to Avoid

  1. Forgetting the age-based adjustment with fibrinolytics: Patients ≥75 years receive NO bolus and a reduced maintenance dose (0.75 mg/kg vs 1 mg/kg)

  2. Inappropriate dose capping: Do not arbitrarily cap doses at 100 mg in obese patients for ACS treatment (this differs from VTE prophylaxis)

  3. Missing renal impairment: The CrCl <30 mL/min threshold requires once-daily dosing regardless of clinical scenario

  4. Timing errors at PCI: Giving additional enoxaparin when the last dose was <8 hours ago increases bleeding risk unnecessarily

  5. Using fondaparinux for PCI support: This is explicitly contraindicated due to catheter thrombosis risk 1

Monitoring Recommendations

Anti-Xa monitoring is generally not required for standard ACS patients with normal renal function and weight <150 kg. Consider monitoring in:

  • Severe renal impairment (CrCl 15-30 mL/min)
  • Extreme obesity (>150 kg)
  • Recurrent ischemic events on therapy
  • Unexplained bleeding

Target therapeutic anti-Xa levels: 0.5-1.0 IU/mL at 4 hours post-dose.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.